Clinical trials: HPV Vaccine
Cervical Intraepithelial Neoplasia
DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2
To establish therapeutic dendritic cell (DC) vaccines targeting HPV 16/18 E6/E7 protein to block the progression of CIN1/CIN2 to cervical cancer and evaluate the safety and efficacy of the vaccines.
- Trial name
- NCT03870113
- Testing
- Vaccinated group
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital
Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against…
- Trial name
- NCT05996523
- Testing
- PRGN-2009, Pembrolizumab, EKG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Anogenital Human Papilloma Virus Infection
3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.
- Trial name
- NCT01427777
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Guangxi Center for Disease Control and Prevention
Papillomavirus Infections
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
The purpose of this study is to evaluate the safety, tolerability, and the immunological effects of adeno-associated virus-like particle human papillomavirus (AAVLP-HPV) vaccine in healthy adults.
- Trial name
- NCT03929172
- Testing
- AAVLP-HPV
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- 2A Pharma AB
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Knowledge, Attitude
Knowledge and Attitude About HPV Vaccines
The purpose of this study was to analyze the knowledge and attitude about HPV vaccines among Brazilian women after an educative intervention. The knowledge was measured on sexual behavior and HPV infection.
- Conditions
- Knowledge, Attitude, Behavior
- Trial name
- NCT01043341
- Testing
- educative folder
- Where
- Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Universidade Cidade de Sao Paulo
Human Papillomavirus, HIV-1 Infection
A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years
The purpose of this study is to determine sustained immunogenicity of the quadrivalent vaccine 'Gardasil', 48 months after initial vaccination, among HIV-1 infected boys and girls age 9-14 years.
- Trial name
- NCT01446718
- Testing
- Gardasil vaccine
- Volunteers
- 179 people
- Sponsor
- Kenya Medical Research Institute
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Precancerous Condition
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine…
- Trial name
- NCT00513526
- Testing
- Gardasil
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- AIDS Malignancy Consortium
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV).
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Trial name
- NCT06098690
- Testing
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
HPV-associated Cancer
An Extended Follow-Up Study of the HPV Vaccine Delayed Booster Trial
This is an extended follow-up study to follow-up study participants who received 1 booster dose of Gardasil 9 in the "HPV vaccine delayed booster trial." This was a prospective, single-arm, open-label, non-randomized, phase IIa…
- Trial name
- NCT04688476
- Where
- 2 sites in United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Cervical High Grade Squamous Intraepithelial Lesion
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors.
- Trial name
- NCT01928225
- Testing
- Human Papillomavirus vaccine
- Volunteers
- 180 people
- Sponsor
- University of Witwatersrand, South Africa
Cervical Cancer
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously…
- Trial name
- NCT07077980
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Anhui Provincial Hospital
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00578227
- Testing
- Cervarix™, Twinrix ™ Paediatric
- Where
- 21 sites in Canada, Denmark and 2 more
- Volunteers
- 814 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to…
- Trial name
- NCT01493154
- Testing
- DNA Vaccine, Cyclophosphamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Papillomavirus Infections
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
This study aims to demonstrate that a 2-dose regimen of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) to each of the…
- Trial name
- NCT05450705
- Testing
- 9vHPV vaccine
- Where
- 2 sites in China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
- Trial name
- HPV CSP01 (NCT00956553)
- Testing
- Cervarix, Gardasil
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Public Health England